Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$7.80 +1.0%	$7.74	$5.01 ▼ $18.71	$46.02M	0.18	118,548 shs	20,119 shs
AVRO AVROBIO		$9.98	$0.88 ▼ $1.65	$62.85M	1.23	269,831 shs	206,800 shs
BVNRY Bavarian Nordic	$8.83 +0.2%	$8.55	$6.60 ▼ $14.60	$2.08B	1.36	2,980 shs	3,558 shs
CGEN Compugen	$1.73 -2.8%	$1.53	$1.13 ▼ $2.66	$158.84M	2.57	369,380 shs	221,000 shs
MESO Mesoblast	$12.12 +11.3%	$11.35	$5.78 ▼ $22.00	$1.39B	2.39	276,075 shs	472,119 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	-3.02%	-2.03%	-0.77%	+28.45%	-9.18%
AVRO AVROBIO	0.00%	0.00%	0.00%	0.00%	0.00%
BVNRY Bavarian Nordic	-0.17%	+1.73%	+2.04%	+20.11%	+6.66%
CGEN Compugen	+7.23%	+9.20%	+19.46%	+26.24%	+5.95%
MESO Mesoblast	-0.27%	+7.19%	+2.64%	-8.49%	+59.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATRA Atara Biotherapeutics	4.3962 of 5 stars	3.3	3.0	0.0	4.7	2.6	2.5	0.6
AVRO AVROBIO	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CGEN Compugen	2.287 of 5 stars	3.5	3.0	0.0	0.0	3.8	0.0	0.0
MESO Mesoblast	2.1315 of 5 stars	3.5	1.0	0.0	0.0	3.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.57	Moderate Buy	$17.75	127.56% Upside
AVRO AVROBIO	0.00	N/A	N/A	N/A
BVNRY Bavarian Nordic	0.00	N/A	N/A	N/A
CGEN Compugen	3.00	Buy	$4.00	131.21% Upside
MESO Mesoblast	3.00	Buy	$18.00	48.51% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$128.94M	0.36	N/A	N/A	($16.89) per share	-0.46
AVRO AVROBIO	N/A	N/A	N/A	N/A	$2.13 per share	N/A
BVNRY Bavarian Nordic	$829.12M	2.52	$1.01 per share	8.70	$6.99 per share	1.26
CGEN Compugen	$27.86M	5.54	N/A	N/A	$0.62 per share	2.79
MESO Mesoblast	$5.90M	262.49	N/A	N/A	$4.21 per share	2.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	-$85.40M	-$3.72	N/A	N/A	N/A	-7.83%	N/A	-14.51%	8/11/2025 (Estimated)
AVRO AVROBIO	$12.16M	$0.69	2.03	N/A	N/A	N/A	-50.52%	-47.13%	N/A
BVNRY Bavarian Nordic	$143.26M	$0.80	11.03	8.41	N/A	21.11%	11.89%	9.32%	8/22/2025 (Estimated)
CGEN Compugen	-$14.23M	-$0.16	N/A	N/A	N/A	-51.27%	-24.51%	-12.19%	8/5/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)

Latest BVNRY, MESO, AVRO, CGEN, and ATRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/19/2025	Q1 2025	CGEN Compugen	-$0.06	-$0.08	-$0.02	-$0.08	$3.70 million	$2.28 million
5/15/2025	Q1 2025	ATRA Atara Biotherapeutics	-$3.07	$3.50	+$6.57	$3.50	$4.30 million	$98.10 million
5/9/2025	Q1 2025	BVNRY Bavarian Nordic	N/A	$0.13	N/A	$0.13	N/A	$189.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
AVRO AVROBIO	N/A	N/A	N/A	N/A	N/A
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	0.57	0.57
AVRO AVROBIO	N/A	26.17	26.17
BVNRY Bavarian Nordic	N/A	2.81	1.44
CGEN Compugen	N/A	5.09	5.09
MESO Mesoblast	0.22	0.96	0.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
AVRO AVROBIO	62.63%
BVNRY Bavarian Nordic	N/A
CGEN Compugen	12.22%
MESO Mesoblast	1.43%

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	4.00%
AVRO AVROBIO	9.20%
BVNRY Bavarian Nordic	N/A
CGEN Compugen	9.50%
MESO Mesoblast	18.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	330	5.96 million	5.72 million	Optionable
AVRO AVROBIO	13	44.89 million	40.76 million	Optionable
BVNRY Bavarian Nordic	1,611	236.57 million	N/A	Not Optionable
CGEN Compugen	70	89.24 million	80.76 million	Optionable
MESO Mesoblast	80	127.78 million	103.76 million	Optionable

BVNRY, MESO, AVRO, CGEN, and ATRA Headlines

Recent News About These Companies

Mesoblast (NASDAQ:MESO) Shares Gap Up - What's Next?

July 1 at 10:56 AM | marketbeat.com

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor

July 1 at 8:46 AM | benzinga.com

Financial Survey: Mesoblast (NASDAQ:MESO) vs. Rallybio (NASDAQ:RLYB)

July 1 at 4:19 AM | americanbankingnews.com

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

June 30 at 8:36 PM | globenewswire.com

Mesoblast (MESO) Gets 7 Years of Orphan-drug Exclusive Approval from US FDA for Ryoncil

June 29 at 3:17 PM | msn.com

Mesoblast (NASDAQ:MESO) Shares Down 4.2% - Here's What Happened

June 23, 2025 | marketbeat.com

Mesoblast Limited (MSB.AX)

June 22, 2025 | finance.yahoo.com

Mesoblast (NASDAQ:MESO) Shares Gap Down - Time to Sell?

June 20, 2025 | marketbeat.com

Prosperity Wealth Management Inc. Has $608,000 Stock Position in Mesoblast Limited (NASDAQ:MESO)

June 18, 2025 | marketbeat.com

Mesoblast Limited (NASDAQ:MESO) Shares Purchased by GAMMA Investing LLC

June 16, 2025 | marketbeat.com

Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’

June 12, 2025 | msn.com

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

June 11, 2025 | globenewswire.com

Mesoblast (NASDAQ:MESO) Shares Gap Down - Should You Sell?

June 11, 2025 | marketbeat.com

Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval

June 10, 2025 | finance.yahoo.com

Mesoblast (NASDAQ:MESO) Trading Up 6.2% - Here's What Happened

June 10, 2025 | marketbeat.com

Cantor Fitzgerald Predicts Mesoblast FY2026 Earnings

June 10, 2025 | marketbeat.com

Mesoblast (NASDAQ:MESO) Shares Gap Up - Time to Buy?

June 4, 2025 | marketbeat.com

Which S&P 500 Move Matters?

May 27, 2025 | msn.com

HotCopper Highlights Week 20: Mesoblast FDA miss; Larvotto posts tungsten, Melbana & More

May 16, 2025 | msn.com

Mesoblast Limited: FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil

May 15, 2025 | finanznachrichten.de

Is Mesoblast Limited (MESO) the Best Australian Stock to Buy According to Analysts?

May 15, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVNRY, MESO, AVRO, CGEN, and ATRA Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$7.80 +0.08 (+1.04%)

Closing price 04:00 PM Eastern

Extended Trading

$7.86 +0.06 (+0.77%)

As of 06:14 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

AVROBIO NASDAQ:AVRO

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Bavarian Nordic OTCMKTS:BVNRY

$8.83 +0.02 (+0.18%)

As of 03:54 PM Eastern

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Compugen NASDAQ:CGEN

$1.73 -0.05 (-2.81%)

Closing price 04:00 PM Eastern

Extended Trading

$1.74 +0.01 (+0.58%)

As of 06:20 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Mesoblast NASDAQ:MESO

$12.12 +1.23 (+11.29%)

Closing price 04:00 PM Eastern

Extended Trading

$11.99 -0.13 (-1.07%)

As of 07:55 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time